To obtain further information on time course and mechanisms of cell death after poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, we used HeLa cells exposed for 1 h to the DNA alkylating agent N-methyl-N-nitro-N-nitrosoguanidine. This treatment activated PARP-1 and caused a rapid drop of cellular NAD(H) and ATP contents, culminating 8 -12 h later in cell death. PARP-1 antagonists fully prevented nucleotide depletion and death. Interestingly, in the early 60 min after challenge with N-methyl-N-nitro-N-nitrosoguanidine, mitochondrial membrane potential and superoxide production significantly increased, whereas cellular ADP contents decreased. Again, these events were prevented by PARP-1 inhibitors, suggesting that PARP-1 hyperactivity leads to mitochondrial state 4 respiration. Mitochondrial membrane potential collapsed at later time points (3 h), when mitochondria released apoptosis-inducing factor and cytochrome c. Using immunocytochemistry and targeted luciferase transfection, we found that, despite an exclusive localization of PARP-1 and poly(ADP-ribose) in the nucleus, ATP levels first decreased in mitochondria and then in the cytoplasm of cells undergoing PARP-1 activation. PARP-1 inhibitors rescued ATP (but not NAD(H) levels) in cells undergoing hyper-poly(ADP-ribosyl)ation. Glycolysis played a central role in the energy recovery, whereas mitochondria consumed ATP in the early recovery phase and produced ATP in the late phase after PARP-1 inhibition, further indicating that nuclear poly(ADP-ribosyl)ation rapidly modulates mitochondrial functioning. Together, our data provide evidence for rapid nucleus-mitochondria cross-talk during hyper-poly(ADP-ribosyl)ation-dependent cell death.The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) 1 converts -nicotinamide-adenine dinucleotide (NAD) into polymers of poly(ADP-ribose) (PAR), which participate in regulating nuclear homeostasis (1). However, once hyperactivated by genotoxic stress, PARP-1 causes NAD and ATP depletion, eventually leading to irreversible cellular energy failure and necrotic death (2-6). The pathophysiological significance of PARP-1 hyperactivation is well exemplified by the remarkable therapeutic efficacy of PARP-1 inhibitors in experimental models of disorders characterized by DNA damage, such as ischemia, diabetes, shock, inflammation, and cancer (7). Recently, several studies have broadened the role of poly(ADP-ribosyl)-ation in cell killing, showing that PARP-1 activation also occurs during apoptosis, and inhibition of PAR formation impairs activation of the apoptotic machinery (for reviews see Refs. 8 and 9). In particular, it has been reported that PARP-1 prompts a cascade of events leading to PAR-dependent mitochondrial dysfunction and rapid release of apoptosis-inducing factor (AIF) (10 -12).Despite their pathogenetic relevance, however, molecular mechanisms underlying energetic derangement during PARP-1 hyperactivation still wait to be clarified. For instance, whether nuclear or mitochondrial PARP-1 hyperactivity triggers mi...